Also from this source


You just read:

NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

News provided by

NGM Bio

Apr 22, 2017, 10:00 ET